Back to Search
DAVID SPIGEL, M.D.
M.D.
Medical Oncology Physician
NPI: 1427074210IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
37373(TN)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
UNIVERSITY OF TENNESSEE, HSC, COLLEGE OF MEDICINE
Class of 1996
Research & Publications (20)
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
PMID 18438878·Cancer·2008
3-trial
What is the role of novel taxanes in non-small-cell lung cancer?
PMID 19419925·Clin Lung Cancer·2008
6-review
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
PMID 17805064·J Thorac Oncol·2007
3-trial
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
PMID 16179100·Clin Lung Cancer·2005
3-trial
Chemotherapy in metastatic and locally advanced non-small cell lung cancer.
PMID 14508860·Semin Surg Oncol·2003
6-review
Evolving role of irinotecan in small-cell lung cancer.
PMID 16258436·Clin Adv Hematol Oncol·2003
6-review
Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
PMID 14715107·Clin Breast Cancer·2003
6-review
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
PMID 19661042·Clin Breast Cancer·2009
3-trial
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
PMID 19525191·Clin Lymphoma Myeloma·2009
3-trial
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
PMID 19299236·Clin Breast Cancer·2009
3-trial
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
PMID 19288572·Cancer·2009
3-trial
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
PMID 19114685·J Clin Oncol·2009
3-trial
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
PMID 18543319·Cancer·2008
3-trial
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
PMID 18952556·Clin Breast Cancer·2008
3-trial
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
PMID 18802157·J Clin Oncol·2008
4-observational
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
PMID 18650154·Clin Breast Cancer·2008
3-trial
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
PMID 18621625·Clin Lung Cancer·2008
3-trial
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
PMID 18458038·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 25TH AVE N, STE 100
NASHVILLE, TN 37203 - Phone
- (615) 329-0570
Quick Facts
- NPI
- 1427074210
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 20
Are you this provider?
Claim Your Profile